The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies

ISSN： 1746-0751

Source： Regenerative Medicine, Vol.7, Iss.3, 2012-05, pp. : 429-438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human Myoblast Genome Therapies and Devices in Regenerative Medicine

Recent Patents on Regenerative Medicine, Vol. 1, Iss. 1, 2011-01 ,pp. : 88-117

Bentham Science Publishers

Access to resources Recommend Favorite

Cellular replacement and regenerative medicine therapies in ischemic stroke

By Thwaites John W Reebye Vikash Mintz Paul Levicar Natasa Habib Nagy

Regenerative Medicine, Vol. 7, Iss. 3, 2012-05 ,pp. : 387-395

Future Medicine

Access to resources Recommend Favorite

Interview: The commercialization of regenerative medicine into a routine healthcare offering

By Deans Robert

Regenerative Medicine, Vol. 8, Iss. 3, 2013-05 ,pp. : 251-256

Future Medicine

Access to resources Recommend Favorite

Interview: Commercial translation of cell-based therapies and regenerative medicine: learning by experience

By Haseltine William A

Regenerative Medicine, Vol. 6, Iss. 4, 2011-07 ,pp. : 431-435

Future Medicine

Access to resources Recommend Favorite

Regenerative medicine

By Minger Stephen L

Regenerative Medicine, Vol. 1, Iss. 1, 2006-01 ,pp. : 1-2

Future Medicine

Access to resources Recommend Favorite